home / stock / gnftf / gnftf short
Short Information | Genfit Ord (OTCMKTS:GNFTF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 9,824 |
Total Actual Volume | 14,370 |
Short Trends | |
---|---|
Cover Days | 5 |
Short Days | 13 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 491 |
Average Short Percentage | 66.44% |
Is there a GNFTF Short Squeeze or Breakout about to happen?
See the GNFTF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
06-24-2024 | $0 | $5.53 | $0 | $0 | 3 | 3 | 100% |
06-10-2024 | $0 | $5.53 | $0 | $0 | 55 | 55 | 100% |
06-07-2024 | $5.5 | $5.53 | $5.53 | $5.5 | 1,440 | 1,228 | 85.28% |
06-05-2024 | $0 | $5.13 | $0 | $0 | 15 | 15 | 100% |
06-04-2024 | $0 | $5.13 | $0 | $0 | 75 | 15 | 20% |
12-29-2023 | $3.45 | $3.45 | $3.45 | $3.45 | 1,201 | 1,200 | 99.92% |
05-09-2023 | $4.39 | $4.39 | $4.39 | $4.39 | 2,278 | 2,278 | 100% |
02-24-2023 | $4.39 | $4.39 | $4.39 | $4.39 | 200 | 200 | 100% |
10-12-2021 | $3.4 | $3.4 | $3.4 | $3.4 | 100 | 100 | 100% |
02-23-2021 | $5.19 | $5.19 | $5.19 | $5.19 | 500 | 300 | 60% |
02-22-2021 | $5.34 | $5.44 | $5.44 | $5.34 | 275 | 100 | 36.36% |
02-10-2021 | $6.64 | $6 | $6.64 | $6 | 2,272 | 815 | 35.87% |
12-28-2020 | $4.8 | $4.75 | $4.8 | $4.75 | 1,140 | 1,040 | 91.23% |
12-10-2020 | $5.49 | $5.49 | $5.49 | $5.49 | 350 | 50 | 14.29% |
12-07-2020 | $5.45 | $5.45 | $5.45 | $5.45 | 1,200 | 200 | 16.67% |
11-30-2020 | $5.5 | $5.5 | $5.5 | $5.5 | 1,000 | 897 | 89.7% |
11-19-2020 | $4.76 | $4.76 | $4.76 | $4.76 | 133 | 30 | 22.56% |
11-17-2020 | $4.7 | $4.785 | $4.785 | $4.7 | 300 | 100 | 33.33% |
11-11-2020 | $4.59 | $4.9 | $4.9 | $4.59 | 583 | 303 | 51.97% |
10-20-2020 | $4.283 | $4.28 | $4.283 | $4.28 | 1,250 | 895 | 71.6% |
News, Short Squeeze, Breakout and More Instantly...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...